Tyr50

Site Information
RNLLsVAykNVVGAR SwissProt Entrez-Gene
Blast this site against: NCBI SwissProt PDB
Site Group ID: 12432961
Available spectra: 1 CST

In vivo Characterization
Methods used to characterize site in vivo:	mass spectrometry ( 1 , 2 , 3 , 4 , 5 , 6 , 7 , 8 , 9 , 10 , 11 , 12 , 13 )
Disease tissue studied:	liver cancer, surrounding tissue ( 10 ) , lung cancer ( 1 , 2 , 3 , 4 , 5 , 11 , 12 ) , non-small cell lung cancer ( 3 , 4 , 5 ) , non-small cell lung adenocarcinoma ( 1 , 2 , 3 , 4 , 5 ) , non-small cell large cell lung carcinoma ( 3 ) , non-small cell squamous cell lung carcinoma ( 2 ) , ovarian cancer ( 13 ) , thymic carcinoma ( 7 )
Relevant cell line - cell type - tissue:	'liver, para-cholangiocellular carcinoma tissue' ( 8 ) , Cal-12T (pulmonary) ( 5 ) , DMS153 (pulmonary) ( 4 ) , HCC15 (pulmonary) ( 2 ) , HCC44 (pulmonary) ( 5 ) , HCC78 (pulmonary) ( 3 ) , HeLa (cervical) ( 9 ) , liver ( 10 ) , LOU-NH91 (squamous) ( 2 ) , lung ( 2 , 3 , 4 , 5 , 11 , 12 ) , NCI-H1437 (pulmonary) ( 4 , 5 ) , NCI-H1666 (pulmonary) ( 5 ) , NCI-H1703 (squamous) ( 2 ) , NCI-H1781 (pulmonary) ( 3 ) , NCI-H2073 (pulmonary) ( 2 , 4 ) , NCI-H209 (pulmonary) ( 4 ) , NCI-H2228 (pulmonary) ( 3 ) , NCI-H2342 (pulmonary) ( 2 ) , NCI-H2405 (pulmonary) ( 5 ) , NCI-H3122 (pulmonary) ( 3 ) , NCI-H661 (pulmonary) ( 3 ) , NCI-H838 (pulmonary) ( 4 ) , ovary ( 13 ) , PC9 (pulmonary) ( 1 ) , PC9-IR (pulmonary) ( 1 ) , thymus ( 7 )

References
1	Tsai CF, et al. (2015) Large-scale determination of absolute phosphorylation stoichiometries in human cells by motif-targeting quantitative proteomics. Nat Commun 6, 6622 25814448 Curated Info
2	Rikova K, Hall B (2013) CST Curation Set: 20739, 21166, 30167, 30168, 30169; Year: 2013; Biosample/Treatment: cell line, H2342, H2073, Lou-NH91, HCC15, H1703; Disease: -; TMT: Y; Specificities of Antibodies Used to Purify Peptides prior to LCMS: pY, p[ST], RXXp[ST], pSQ, p[ST]QG, LXRXXp[ST], p[ST]P Curated Info
3	Rikova K, Hall B (2013) CST Curation Set: 20740, 21167, 30170, 30171, 30172; Year: 2013; Biosample/Treatment: cell line, H2228, H3122, HCC78, H661, H1781; Disease: -; TMT: Y; Specificities of Antibodies Used to Purify Peptides prior to LCMS: pY, p[ST], RXXp[ST], pSQ, p[ST]QG, LXRXXp[ST], p[ST]P Curated Info
4	Rikova K, Hall B (2013) CST Curation Set: 20742, 21169, 30176, 30177, 30178; Year: 2013; Biosample/Treatment: cell line, H838, DMS153, H2073, H209, H1437; Disease: -; TMT: Y; Specificities of Antibodies Used to Purify Peptides prior to LCMS: pY, p[ST], RXXp[ST], pSQ, p[ST]QG, LXRXXp[ST], p[ST]P Curated Info
5	Rikova K, Hall B (2013) CST Curation Set: 20741, 21168, 30173, 30174, 30175; Year: 2013; Biosample/Treatment: cell line, H1666, CAL-12T, H2405, HCC44, H1437; Disease: -; TMT: Y; Specificities of Antibodies Used to Purify Peptides prior to LCMS: pY, p[ST], RXXp[ST], pSQ, p[ST]QG, LXRXXp[ST], p[ST]P Curated Info
6	Rikova K (2012) CST Curation Set: 14271; Year: 2012; Biosample/Treatment: cell line, Tumor pilot study 2mg/untreated; Disease: -; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: p[STY]) Curated Info
7	Li Y (2011) CST Curation Set: 10458; Year: 2011; Biosample/Treatment: tissue, thymus/untreated; Disease: thymic carcinoma; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: pY Antibodies Used to Purify Peptides prior to LCMS: Phospho-Tyrosine Mouse mAb (P-Tyr-100) Cat#: 9411, PTMScan(R) Phospho-Tyr Motif (Y*) Immunoaffinity Beads Cat#: 1991 Curated Info
8	Gu TL, et al. (2011) Survey of tyrosine kinase signaling reveals ROS kinase fusions in human cholangiocarcinoma. PLoS One 6, e15640 21253578 Curated Info
9	Kettenbach AN, et al. (2011) Quantitative phosphoproteomics identifies substrates and functional modules of aurora and polo-like kinase activities in mitotic cells. Sci Signal 4, rs5 21712546 Curated Info
10	Gu T (2010) CST Curation Set: 9489; Year: 2010; Biosample/Treatment: tissue, liver/untreated; Disease: liver cancer; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: pY Antibodies Used to Purify Peptides prior to LCMS: Phospho-Tyrosine Mouse mAb (P-Tyr-100) Cat#: 9411, PTMScan(R) Phospho-Tyr Motif (Y*) Immunoaffinity Beads Cat#: 1991 Curated Info
11	Hu Y (2010) CST Curation Set: 8758; Year: 2010; Biosample/Treatment: tissue, lung/untreated; Disease: lung cancer; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: pY Antibodies Used to Purify Peptides prior to LCMS: Phospho-Tyrosine Mouse mAb (P-Tyr-100) Cat#: 9411, PTMScan(R) Phospho-Tyr Motif (Y*) Immunoaffinity Beads Cat#: 1991 Curated Info
12	Hu Y (2010) CST Curation Set: 8947; Year: 2010; Biosample/Treatment: tissue, lung/untreated; Disease: lung cancer; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: pY Antibodies Used to Purify Peptides prior to LCMS: Phospho-Tyrosine Mouse mAb (P-Tyr-100) Cat#: 9411, PTMScan(R) Phospho-Tyr Motif (Y*) Immunoaffinity Beads Cat#: 1991 Curated Info
13	Ren H (2010) CST Curation Set: 8889; Year: 2010; Biosample/Treatment: tissue, ovary/untreated; Disease: ovarian cancer; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: pY Antibodies Used to Purify Peptides prior to LCMS: Phospho-Tyrosine Mouse mAb (P-Tyr-100) Cat#: 9411, PTMScan(R) Phospho-Tyr Motif (Y*) Immunoaffinity Beads Cat#: 1991 Curated Info